论文部分内容阅读
为探讨增殖细胞核抗原（PCNA）在估计胆管瘤预后中价值，应用免疫组化方法研究胆管癌及其良性病变PCNA蛋白的表达。结果显示：30例胆管癌患者PCNA蛋白阳性表达率为86．7％（26／30），与良性病变组比较有显著性差异（P<0．01），表明癌变组织具有较强的细胞增殖活性。Ⅱ期胆管癌PCNA高增殖组（8例）平均生存期13个月，低增殖组（10例）为26个月，两组有显著性差异（P＜005）。提示PCNA对估计胆管癌预后有一定价值。
To investigate the value of proliferating cell nuclear antigen (PCNA) in estimating the prognosis of cholangiocarcinoma, immunohistochemistry was used to study the expression of PCNA protein in cholangiocarcinoma and benign lesions. The results showed that the positive expression rate of PCNA protein in 30 cases of cholangiocarcinoma was 86.7% (26/30), which was significantly different from that in benign lesions (P<0.01), indicating that the cancerous tissue had strong cell proliferation. active. The average survival time of PCNA high-proliferation group (8 cases) in stage II cholangiocarcinoma was 13 months, and 26 months in low-proliferation group (10 cases). There was a significant difference between the two groups (P < 005). It is suggested that PCNA has some value in estimating the prognosis of cholangiocarcinoma.